Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (25)

2020

  1. Inflammatory-Related Clinical and Metabolic Outcomes in COVID-19 Patients

    Mediators of inflammation, Vol. 2020, pp. 2914275

2015

  1. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2005

  1. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT

    Journal of Clinical Microbiology, Vol. 43, Núm. 8, pp. 3860-3868

  2. Treatment response and drug resistance in patients infected with HIV type 1 group O viruses

    AIDS Research and Human Retroviruses, Vol. 21, Núm. 7, pp. 602-607

2003

  1. Can drug resistance mutations influence the measurement of plasma HIV-RNA by different viral load techniques?

    AIDS Patient Care and STDs, Vol. 17, Núm. 7, pp. 321-324

  2. High rate of resistance to antiretroviral drugs among HIV-infected prison inmates

    Medical Science Monitor, Vol. 9, Núm. 6

  3. Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes

    HIV Clinical Trials, Vol. 4, Núm. 6, pp. 372-381

  4. Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients

    Journal of Clinical Microbiology, Vol. 41, Núm. 9, pp. 4421-4423

  5. Toxicidad mitocondrial de los antirretrovirales: Diagnóstico y monitorizacíon

    Medicina Clinica, Vol. 121, Núm. 8, pp. 310-315

  6. Transmission of HIV type 1 through blood transfusion from an antibody-negative/p24 antigen-negative donor

    AIDS Research and Human Retroviruses, Vol. 19, Núm. 6, pp. 447-448

2002

  1. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors

    International Journal of Antimicrobial Agents, Vol. 20, Núm. 6, pp. 438-443

  2. Genetic mechanisms of resistance to NRTI and NNRTI

    HIV Clinical Trials, Vol. 3, Núm. 3, pp. 237-248

  3. Genetic mechanisms of resistance to protease inhibitors and entry inhibitors

    HIV Clinical Trials, Vol. 3, Núm. 3, pp. 249-257

  4. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir

    AIDS, Vol. 16, Núm. 14, pp. 1964-1966

  5. Mechanisms of resistance to antiretroviral drugs - Clinical implications

    AIDS Reviews, Vol. 4, Núm. 2, pp. 64-82

  6. Prevalence of G333D/E in naive and pretreated HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 18, Núm. 12, pp. 857-860

  7. Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir [7]

    Clinical Infectious Diseases